Testing effectiveness (Phase 2)Study completedNCT03842189
What this trial is testing
Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Who this might be right for
Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC 25